

ACTLiquid™ Lite

A Simple Blood Draw. A Clearer Tomorrow.

Actionable Liquid-Based NGS Assay for Treatment Selection and Dynamic Monitoring.


USE WHEN



Tissue is Limited or Unavailable



Evaluating Systemic or Targeted Therapy Options



Monitoring for Suspected Disease Progression or Recurrence



Assessing Next-Line Therapeutic Strategies upon Drug Resistance

ACTLiquid™ Lite Assay Specification

Test Specifications

Number of Genes Tested	102
Genomic Alterations & Analysis Features	• Single Nucleotide Variants (SNVs) • Small Insertions and Deletions (InDels) • Copy Number Alterations (CNAs) • Fusions • Microsatellite Instability (MSI)
Specimen Requirements	Whole Blood: 2 × 8–10 mL Streck Tubes (16–20 mL) Pleural Effusion: 2 × 8–10 mL Streck Tubes (16–20 mL)
Storage and Stability	Room Temperature (18–25°C); Specimen Collection ≤ 7 Days
Turnaround Time [#]	8 Working Days

[#] From receipt of qualified samples at our CAP-accredited laboratory.

Performance Specifications

Alteration Type	Limit of Detection (LoD)		Sensitivity [‡]		Specificity [‡]	Reportable Threshold
	10 ng	20 ng	10 ng	20 ng		
SNVs / InDels	0.50% VAF	0.25% VAF	96.7%	98.9%	>99.9%	≥0.10% ^{&}
CNAs	2.1–3.0 Copies	2.1–3.0 Copies	100%	100%	>99.9%	Gain: ≥1.30 Fold Change Loss: ≤0.35 Fold Change
Fusions	0.50% VAF	0.25% VAF	100%	100%	>99.9%	≥3 Reads
MSI[§]	–	3% Tumor Fraction	–	–	–	MSI – H: Score ≥0.10 MSS: Score <0.10

[‡] Analytical performance was established under defined validation conditions.

[&] Reportable Range: ≥ 0.1% VAF for predefined actionable hotspots; ≥ 0.25% VAF for other reportable regions.

[§] MSI performance was evaluated using 20 ng DNA input; evaluation of other performance metrics was limited by the availability of suitable specimens.

ACTLiquid™ Lite Gene List

◆ SNV / InDel ■ CNA (Gain)
▲ Fusion ● CNA (Loss)

Types of Gene Mutations Analyzed: SNVs, InDels, CNAs, Fusions and MSI


AKT1 ◆	ALK ▲ ◆	APC ◆	AR ■ ◆	ARAF ◆	ARID1A ◆	ATM ◆	ATR ◆
ATRX ◆	BARD1 ◆	BRAF ▲ ■ ◆	BRCA1 ● ◆	BRCA2 ● ◆	BRIP1 ◆	CCND1 ■ ◆	CCNE1 ■ ◆
CD74 ▲	CDK12 ◆	CDK4 ■ ◆	CDK6 ■ ◆	CDKN2A ● ◆	CDKN2B ◆	CHEK1 ◆	CHEK2 ◆
CTNNB1 ◆	EGFR ▲ ■ ◆	EML4 ▲	ERBB2 ■ ◆	ERBB3 ◆	ERBB4 ◆	ERG ▲	ESR1 ▲ ◆
ETV6 ▲	EZH2 ◆	FANCA ◆	FANCL ◆	FBXW7 ◆	FGFR1 ▲ ■ ◆	FGFR2 ▲ ■ ◆	FGFR3 ▲ ◆
H3-3A ◆	H3C2 ◆	HDAC2 ◆	HRAS ◆	IDH1 ◆	IDH2 ◆	JAK1 ◆	JAK2 ◆
KDM6A ◆	KEAP1 ◆	KIT ■ ◆	KRAS ■ ◆	MAP2K1 ◆	MAP2K2 ◆	MDM2 ■ ◆	MDM4 ◆
MET ▲ ■ ◆	MLH1 ◆	MRE11 ◆	MSH2 ◆	MSH6 ◆	MTAP ● ◆	MTOR ◆	MUTYH ◆
MYC ■ ◆	MYCN ■ ◆	NBN ◆	NF1 ◆	NF2 ◆	NRAS ◆	NRG1 ▲	NTRK1 ▲ ◆
NTRK2 ▲ ◆	NTRK3 ▲ ◆	PALB2 ◆	PDGFRA ■ ◆	PIK3CA ■ ◆	PIK3R1 ◆	PMS2 ◆	POLD1 ◆
POLE ◆	PPP2R1A ◆	PTEN ● ◆	RAD51B ◆	RAD51C ◆	RAD51D ◆	RAD54L ◆	RAF1 ◆
RB1 ● ◆	RET ▲ ◆	ROS1 ▲ ◆	SMAD4 ◆	SMARCA2 ◆	SMARCA4 ◆	SMARCB1 ◆	STK11 ◆
TERT ◆	TMPRSS2 ▲	TP53 ◆	TSC1 ◆	TSC2 ◆	VHL ◆		

* Bolded entries indicate dedicated assay design, including MET exon 14 skipping and TERT promoter regions.

Know the Stage. Give the Right Message.

As cancer progresses and adapts, liquid biopsy allows dynamic monitoring of tumor evolution to guide personalized treatment adjustments at critical clinical milestones.

ctDNA Changes Across the Cancer Journey



Different Clinical Needs Require Different ctDNA Tests

Intended Use

Localized Cancer

MRD Detection / Molecular Relapse


Treatment Monitoring (Neoadjuvant / Adjuvant)

Metastatic Disease

Molecular Genotyping

Treatment Monitoring / Resistance Mutations

ctDNA Ratio or Limit of Detection (varies by variant type)




1. Friends of Cancer Research Annual Meeting 2021

2. Pantel K, Alix-Panabières C. Nat Rev Clin Oncol. 2019. Tie J, et al. J Clin Oncol. 2022.

ACTLiquid™ Lite Workflow

From specimen collection to clinical reporting, each sample undergoes multiple essential steps to generate clinically interpretable molecular results.



ACTLiquid™ Lite Report

See Beyond a Single Result.

ACTLiquid™ Lite reports synthesize complex genomic findings into intuitive, evidence-backed summaries designed to support rapid clinical interpretation and longitudinal comparison.

1 Actionable Summary

Highlights clinically relevant variants and biomarkers alongside corresponding treatment options for rapid clinical review.

Report Summary for Actionable Variants/Biomarkers

Immune Checkpoint Inhibitor (ICI)-Related Biomarkers

Detected Biomarker Status	Corresponding Therapies
Microsatellite Status (MSI): Microsatellite stable	-
S Sensitive R Resistant	

Variants/Biomarkers with Clinical Significance (Targeted Therapy)

Genomic Alterations	Evidence Level 1, 2 (FDA-approved, NCCN guideline)	Evidence Level 3A, 3B, 4 (Others)
ATM S877fs	S Olaparib, Talazoparib	S Niraparib, Rucaparib

Variants/Biomarkers with Clinical Significance (Hormonal Therapy)

Genomic Alterations	Evidence Level 1, 2 (FDA-approved, NCCN guideline)	Evidence Level 3A, 3B, 4 (Others)
AR Amplification	-	S Bicalutamide, Leuprolide R Abiraterone, Enzalutamide, Tamoxifen

Cancer-Specific Genes Evaluated

FDA-Approved Biomarkers Assessed by This Assay: ATM, ATR, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCA, FANCL, MLH1, NBN, PALB2, RAD51B, RAD51C, RAD51D, RAD54L, PTEN

Dynamic Monitoring of Biomarkers

Report No.	AA-26-00001_Lite	AA-26-00100_Lite	AA-26-00200_Lite
Sample Collection Date	Sep 6, 2025	Jan 1, 2026	Jul 6, 2026
Tumor Fraction	50%	20%	15%
MSI Status	MSS	MSS	MSS
ATMS877fs (AF)	5.2%	3.6%	2.7%
TP53 G245S (AF)	3.1%	2.2%	1.0%
AR amplification (FC)	1.75	1.6	1.46

Not detected: The specified biomarker was not detected in the sample.

MSS: Microsatellite stable; MSI-H: Microsatellite instability-high.

AF: Allele frequency

FC: Fold change

2 Evidence Level

Categorizes therapeutic options by established clinical evidence levels to assist oncologists in evaluating treatment strategies.

3 Dynamic Table

Side-by-side comparison of up to 5 consecutive test results, tracking changes in tumor fraction, biomarker status, and emerging resistance mutations over time.



www.actgenomics.com

service@actgenomics.com

+886-2-2795-3660



©2026 ACT Genomics Co., LTD. All Rights Reserved. It is possible that the test may return with no abnormal mutation identified for certain genes or part of the test results may not be available due to the technical limitations of the test itself and/or an individual's genetic differences and/or intra- or inter-tumoral heterogeneity even the test has been conducted under standard process. This material (including the test and the results) therefrom are intended for educational purposes only for the use of healthcare professionals and do not replace independent professional judgement. This material (including the test and the results) shall at no time be deemed a diagnostic or medical treatment recommendation to any individual. No representation, warranty, express or implied, is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinions which may be contained herein. The test takers shall always consult their healthcare professionals for any enquiries of clinical interpretation of the test results.

ACT GENOMICS is a registered trademark of ACT Genomics Co., LTD., and ACTLiquid™ is a trademark of ACT Genomics Co., LTD.

Member of Delta Group